Submitted by Anonymous (not verified) on 4 September 2024 - 16:34
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 8, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 8, Status: Authorised